|
Pronunciation |
|
(fla
VOKS
ate) |
|
|
U.S. Brand
Names |
|
Urispas® |
|
|
Generic
Available |
|
No |
|
|
Synonyms |
|
Flavoxate Hydrochloride |
|
|
Pharmacological Index |
|
Antispasmodic Agent, Urinary |
|
|
Use |
|
Antispasmodic to provide symptomatic relief of dysuria, nocturia, suprapubic
pain, urgency, and incontinence due to detrusor instability and hyper-reflexia
in elderly with cystitis, urethritis, urethrocystitis, urethrotrigonitis, and
prostatitis |
|
|
Pregnancy Risk
Factor |
|
B |
|
|
Contraindications |
|
Pyloric or duodenal obstruction, GI hemorrhage, GI obstruction; ileus;
achalasia; obstructive uropathies of lower urinary tract
(BPH) |
|
|
Warnings/Precautions |
|
May cause drowsiness, vertigo, and ocular disturbances; administer cautiously
in patients with suspected glaucoma |
|
|
Adverse
Reactions |
|
>10%:
Central nervous system: Drowsiness
Gastrointestinal: Xerostomia, dry throat
1% to 10%:
Cardiovascular: Tachycardia, palpitations,
Central nervous system: Nervousness, fatigue, vertigo, headache, hyperpyrexia
Gastrointestinal: Constipation, nausea, vomiting
<1%: Confusion (especially in the elderly), rash, leukopenia, increased
intraocular pressure |
|
|
Overdosage/Toxicology |
|
Symptoms of overdose include clumsiness, dizziness, drowsiness, flushing,
hallucinations, irritability
Supportive care only |
|
|
Drug
Interactions |
|
No data reported |
|
|
Mechanism of
Action |
|
Synthetic antispasmotic with similar actions to that of propantheline; it
exerts a direct relaxant effect on smooth muscles via phosphodiesterase
inhibition, providing relief to a variety of smooth muscle spasms; it is
especially useful for the treatment of bladder spasticity, whereby it produces
an increase in urinary capacity |
|
|
Pharmacodynamics/Kinetics |
|
Onset of action: 55-60 minutes
Metabolism: To methyl; flavone carboxylic acid active
Elimination: 10% to 30% of dose excreted in urine within 6 hours
|
|
|
Usual Dosage |
|
Children >12 years and Adults: Oral: 100-200 mg 3-4 times/day; reduce the
dose when symptoms improve |
|
|
Dietary
Considerations |
|
Should be administered with water on an empty stomach |
|
|
Monitoring
Parameters |
|
Monitor I & O closely |
|
|
Mental Health: Effects
on Mental Status |
|
Drowsiness is common; may cause nervousness |
|
|
Mental Health:
Effects on Psychiatric
Treatment |
|
None reported |
|
|
Dental Health: Local
Anesthetic/Vasoconstrictor
Precautions |
|
No information available to require special precautions |
|
|
Dental Health:
Effects on Dental Treatment |
|
>10% of patients experience dry mouth |
|
|
Patient
Information |
|
Take exactly as directed, with water, preferably on an empty stomach (1 hour
before or 2 hours after meals). Do not use alcohol or OTC medications without
consulting prescriber. You may experience mild drowsiness, nervousness, or
dizziness (use caution when driving or engaging in tasks requiring alertness
until response to drug is known); nausea, vomiting, dry mouth (small frequent
meals, frequent oral care, chewing gum, or sucking hard candy may help);
decreased ability to perspire (avoid extremes of heat); constipation (increased
exercise or dietary fluid and fiber may help). Report vision changes (blurred
vision); rapid heartbeat; or unresolved nausea, vomiting, or constipation.
Breast-feeding precautions: Consult prescriber if
breast-feeding. |
|
|
Nursing
Implications |
|
Monitor I & O closely, incontinence, and PVR |
|
|
Dosage Forms |
|
Tablet, film coated, as hydrochloride: 100
mg |
|
Copyright © 1978-2000 Lexi-Comp Inc. All Rights Reserved
|